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Summary
As the number of preference-based instruments grows, it becomes increasingly important to compare diﬀerent
preference-based measures of health in order to inform an important debate on the choice of instrument. This paper
presents a comparison of two of them, the EQ-5D and the SF-6D (recently developed from the SF-36) across seven
patient/population groups (chronic obstructive airways disease, osteoarthritis, irritable bowel syndrome, lower back
pain, leg ulcers, post menopausal women and elderly). The mean SF-6D index value was found to exceed the EQ-5D
by 0.045 and the intraclass correlation coeﬃcient between them was 0.51. Whilst this convergence lends some
support for the validity of these measures, the modest diﬀerence at the aggregate level masks more signiﬁcant
diﬀerences in agreement across the patient groups and over severity of illness, with the SF-6D having a smaller range
and lower variance in values. There is evidence for ﬂoor eﬀects in the SF-6D and ceiling eﬀects in the EQ-5D. These
discrepancies arise from diﬀerences in their health state classiﬁcations and the methods used to value them. Further
research is required to fully understand the respective roles of the descriptive systems and the valuation methods and
to examine the implications for estimates of the impact of health care interventions. Copyright# 2004 John Wiley
& Sons, Ltd.
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Introduction
Preference-based measures of health, sometimes
called multi-attribute utility scales, are standar-
dised multi-dimensional health state classiﬁcations
which come with pre-existing preference or utility
weights [1] and generate a single index score for
each state of health where full health is one
and zero is equivalent to death. Preference-based
measures of health have become an important set
of instruments for estimating the health state
values used to calculate quality adjusted life years
(QALYs) and are widely used in economic
evaluations alongside clinical trials to value the
beneﬁts of health care.
There are currently an array of preference-
based measures, including the EQ-5D, HUI, 15D,
AQoL, QWB and most recently the SF-6D. These
preference-based measures of health diﬀer con-
siderably in terms of their dimensions, items and
preference weights and there is therefore no reason
why they should generate the same values for a
given patient. A recent review of these measures
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against the criteria of practicality, reliability and
validity of the measures concluded that what
is required, among other things, is a series of
head to head comparisons of the preference-
based measures across a range of conditions and
severity [2].
This paper presents a comparison of two of
them, the EQ-5D and the SF-6D (recently devel-
oped from the SF-36) across seven patient/
population groups (chronic obstructive airways
disease, osteoarthritis, irritable bowel syndrome,
lower back pain, leg ulcers, post menopausal
women and elderly). These are two of the most
widely used general measures of health and this
paper presents the most extensive comparison of
them. The paper begins by presenting a brief
description of the instruments, before setting
out the methods and results of the comparisons
across the seven patient groups. The discussion
seeks to explore the possible reasons for any
divergence and to explore the implications for
their use.
EQ-5D and the SF-6D
The EQ-5D instrument was developed by a multi-
disciplinary group of researchers from seven
centres across ﬁve countries [3]. The ﬁve dimen-
sions are mobility, self-care, usual activities, pain/
discomfort and anxiety/depression (see Table 1)
[4]. They each have three levels and together deﬁne
243 health states. Patients are classiﬁed onto the
EQ-5D by self-completion or interviewer adminis-
tration. The most inﬂuential valuation work to
date with the EQ-5D has been a large-scale survey
undertaken in the UK by the Measurement and
Valuation of Health group at York [5,6]. Their
work elicited trade-oﬀ (TTO) values for 42 health
states deﬁned by the EQ-5D using 2997 interviews
of members of the general population. The 243
health states of the EQ-5D have been valued using
regression methods on this sample. Separate
algorithms are available for diﬀerent socio-demo-
graphic groups. However, it is the so-called A1
tariﬀ (based on 10-year TTO valuations on the
whole survey sample) that is referred to in this
papera (See Table 2). Valuation studies using the
MVH protocol have been repeated in Spain
ðn ¼ 979Þ, Germany ðn ¼ 339Þ, Japan ðn ¼ 621Þ
[7–9]. It has become one of the most widely used
generic measures of health in Europe and has
become commonly used in economic evaluation.
The SF-36 is another generic measure of health
that generates scores across eight dimensions of
health [10]. The eight dimensions are: physical
functioning, role limitation due to physical pro-
blems, social functioning, bodily pain, role limita-
tions due to emotional problems, mental health
and vitality. It has become one of the most widely
used generic measures of health through out the
world, including the USA where it was originally
developed, but was not originally developed for
use in economic evaluation.
A research team at the University of Sheﬃeld in
collaboration with Dr Ware at Boston has
estimated a preference-based single index measure
of health from the SF-36 [11]. The index is
estimated via a health state classiﬁcation called
the SF-6D derived from the SF-36 and is
composed of six multi-level dimensions of health.
It was constructed from a sample of 11 items
selected from the SF-36 to minimise the loss of
descriptive information and deﬁnes 18 000 health
states. A selection of 249 states deﬁned by the SF-
6D have been valued by a representative sample of
the UK general population ðn ¼ 611Þ using the
standard gamble (SG) valuation technique. Like
the EQ-5D, regression models were estimated to
predict single index scores for all health states
deﬁned by the SF-6D. The resultant algorithm can
be used to convert SF-36 data at the individual
level to a preference-based index.b
These instruments have previously been re-
viewed against the criteria of practicality, relia-
bility, and validity. Both instruments have been
found to be practical to use in terms of rates of
response to the questionnaire and levels of
completion. The instruments have been found to
be reliable between test and re-test [12], though
there is evidence that rates of completion of the
SF-36 and hence the SF-6D decline with age [13].
The assessment of validity, however, is rather more
controversial in this area since there is no gold
standard for assessing the social value of health
care interventions [12].
This paper does not directly assess the validity
of these instruments, but addresses the question
of whether or not the two can be used inter-
changeably to estimate the health state value
of patients with diﬀerent medical conditions. It
does this by comparing the two measures in t
erms of the indices they generate across
seven patient samples and examining the distribu-
tion of responses across their health state
classiﬁcations.
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Table 1. The SF-6D and EQ-5D
Level SF-6D EQ-5D
Physical Functioning Mobility
1 Your health does not limit you in vigorous activities 1 No problems walking about
2 Your health limits you a little in vigorous activities 2 Some problems walking about
3 Your health limits you a little in moderate activities 3 Conﬁned to bed
4 Your health limits you a lot in moderate activities Self care
5 Your health limits you a little in bathing and dressing 1 No problems with self-care
6 Your health limits you a lot in bathing and dressing 2 Some problems washing or dres-
sing myself
3 Unable to wash or dress self
Role limitations
1 You have no problems with your work or other regular
daily activities as a result of your physical health or any
emotional problems
2 You are limited in the kind of work or other activities as a
result of your physical health
3 You accomplish less than you would like as a result of
emotional problems Usual activities
4 You are limited in the kind of work or other activities as a
result of your physical health and accomplish less than
you would like as a result of emotional problems
1 No problems with performing
usual activities (e.g. work, study,
housework, family or leisure ac-
tivities)
Social functioning
2 Some problems with performing
usual activities
1 Your health limits your social activities none of the time 3 Unable to perform usual activ-
ities2 Your health limits your social activities a little of the time
3 Your health limits your social activities some of the time
4 Your health limits your social activities most of the time
5 Your health limits your social activities all of the time
Pain Pain/discomfort
1 You have no pain 1 No pain or discomfort
2 You have pain but it does not interfere with your normal
work (both outside the home and housework)
2
3
Moderate pain or discomfort
Extreme pain or discomfort
3 You have pain that interferes with your normal work
(both outside the home and housework) a little bit
4 You have pain that interferes with your normal work
(both outside the home and housework) moderately
5 You have pain that interferes with your normal work
(both outside the home and housework) quite a bit
6 You have pain that interferes with your normal work
(both outside the home and housework) extremely
Mental health Emotions
1 You feel tense or downhearted and low none of the time 1 Not anxious or depressed
2 You feel tense or downhearted and low a little of the time 2 Moderately anxious or depressed
3 You feel tense or downhearted and low some of the time 3 Extremely anxious or depressed
4 You feel tense or downhearted and low most of the time
5 You feel tense or downhearted and low all of the time
Vitality None
1 You have a lot of energy all of the time
2 You have a lot of energy most of the time
3 You have a lot of energy some of the time
4 You have a lot of energy a little of the time
5 You have a lot of energy none of the time
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Methods
Data set
The data set consists of 2436 cases, and covers a
wide rage of patients/populations: lower back pain
chronic obtrusive pulmonary disease irritable
bowel syndrome leg ulcer menopausal women
osteo arthritis, and healthy older women aged
75+. These patients’ samples are described in
more detail below in terms of the study source,
demographic variables and key severity indicators
for each condition.
Lower back pain (LBP; number of observa-
tions=265). These patients were recruited from
General Practices in York (UK) into a randomised
clinical trial of the cost eﬀectiveness of alternative
treatments for lower back pain [14]. Patients were
included if they were aged 20 to 65 presenting with
low back pain of at least 4 weeks duration. The
mean age of the participants was 43 and 61% were
women. On average they had been experiencing
back pain for 17 weeks prior to recruitment, with
most people experiencing pain every day. The data
set consists of the baseline assessment and follow-
up at 3 months following intervention using the
SF-36 and EQ-5D.
Chronic obstructive pulmonary disease (COPD;
number of observations=284). Patients aged 35
years and over, and clinically judged to have
COPD were recruited in a teaching hospital in
Sheﬃeld, UK [15]. Patients with a clinical diag-
nosis of asthma, lung ﬁbrosis and pulmonary
malignancy were excluded. Also excluded were
those whose spirometeric tests gave FEV1 >70%
FVC or FEV1570% FVC but with demonstrable
reversibility. The data set consists of observations
from 156 individuals, of which 76 were male and
80 were female, and mean ages (SD) were 67 (10.4)
years and 62 (10.3) years respectively. Of these,
128 were participated in the follow-up observa-
tions 6 months later.
Irritable bowel syndrome (IBS; number of observa-
tions=322). A sample of 161 IBS suﬀerers known
to their GPs were recruited from six GP practices
in Trent Region in the UK [16]. The practices
themselves were chosen to be representative
geographically and on the basis of deprivation
level and social class. All suitable patients were
sent a letter of explanation and an invitation to
attend consultation for recruitment. This involved
a 15min screening consultation with a project
researcher who took a medical history of their
bowel symptoms. The diagnosis of IBS was
determined by the use of the Rome Criteria. Their
mean age was 47 and 86% were female. All
patients were observed twice.
Leg ulcer (Lu; number of observations=434). All
respondents were recruited into a randomised
control trial of the cost eﬀectiveness of alternative
treatments for venous leg ulcers from eight
community-based clinics [17]. The inclusion criter-
ia were: a venous ulcer below the knee and down
to the foot that had lasted for three months,
agreement to travel to the clinic for the trial, and
written informed consent. The instruments were
administered at 12 weeks and 12 months following
recruitment. The overall response rate was 86%.
Most of the sample was over retirement age and
two thirds were women. More than half had a
mobility problem and three quarters complained
of leg ulcer pain. The median patients had a
baseline ulcer area of 5.6 cm2 and an ulcer that had
lasted for 7 months.
Menopausal women (Mp; number of observations=
293). One thousand and eighty women aged
45–60 were randomly selected from six General
practices in Sheﬃeld, UK and sent a postal
questionnaire containing the EQ-5D, SF-36 and
questions a about menopausal symptoms [18]. Of
these 758 (73%) were returned and had useable
data. The sample used in this paper was the 293
who reported having menopausal symptoms as
deﬁned by the presence of hot ﬂushes. The average
age of the sample was 53.
Osteoporosis (OA; number of observations=
458). These patients were recruited from ﬁve
UK clinics across two distinct settings: a knee
replacement waiting list and a rheumatology clinic
[19]. From these groups, patients were restricted to
those patients with a diagnosis of OA of the knee
made by a rheumatology or orthopaedic specialist.
No further inclusion or exclusion criteria were
applied, so that the recruited patients were likely
to be representative of those seen in everyday
hospital clinical practice in the UK. Patients were
asked to complete the EQ-5D and SF-36 at
baseline and at a 6 month follow-up. Both
assessments have been used in this data set. The
J. Brazier et al.876
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mean age of respondents was 67 and around three
quarters were female. Out of those attending the
rheumatology clinic 41% were classiﬁed by the
clinicians as having severe disease. Completion
rates exceeded 90% for both the instruments.
Healthy older women (number of observations=
380). All respondents were women recruited into
a pilot randomised trial of a treatment for
osteoporosis from four General practices in Shef-
ﬁeld, UK [20]. The inclusion criteria for this study
were all women aged 75 or over willing to
participate in the trial. Women were excluded for
a range of medically related conditions (e.g.
receiving treatment for concurrent malignancy,
women with bilateral hip arthroplasties or internal
ﬁxations of the neck and so forth), but the aim was
to make the trial available to the vast majority of
elderly women. The respondents were Caucasian
females with a mean age of 80.1 and 49% living
alone. Eighty six percent stated that they had
a long limiting standing illness or disability
compared to 73% in the General Household
Survey, but overall they did not diﬀer from the
same age group in terms of use of health services.
These samples were chosen to represent a range
of patient types in terms of dimensions of health
eﬀected by the medical condition, such as those
that impact signiﬁcantly on physical functioning
(such as OA and COPD), pain (LBP and IBS) and
mental health (Mp). They also represent a range in
terms of severity, from those with severe COPD
through to a general population sample (the older
sample). The seven samples provide a good
opportunity to understand the relationship be-
tween the two instruments over a wide range of
health problems.
The overall data set has been formed by
combining ‘baseline’ and ‘follow-up’ observations
from ﬁve of the seven studies, but no distinction is
made in the following analysis. Four of the studies
did not have a speciﬁc intervention, and overall the
changes in health that did take place are too small
for the purposes of this paper.
Analysis
EQ-5D dimensions are what the respondents
reported, and EQ-5D indices are derived using
the MVH standard (A1) algorithm discussed
above. SF-6D dimensions are obtained from the
SF36 responses and the indices estimated using the
methods described above. The analysis is carried
out in two stages. The ﬁrst is based on SF-6D and
EQ-5D self-reported health classiﬁcations, with no
Table 2. Comparing the SF-6D and EQ-5D predictive
models
SF-6D Mean model EQ-5D Random eﬀects model
c 1.000 C 0.919
PF23 0.056 MOB2 0.069
PF4 0.072 MOB3 0.313
PF5 0.080
PF6 0.134 SC2 0.104
SC3 0.213
RL234 0.073
UA2 0.036
SF2 0.080 UA3 0.094
SF3 0.082
SF4 0.091
SF5 0.107
PAIN23 0.052
PAIN4 0.076
PAIN5 0.107 PA2 0.123
PAIN6 0.179 PA3 0.385
MH23 0.062
MH4 0.121 MOOD2 0.071
MH5 0.136 MOOD3 0.237
VIT234 0.017
VIT5 0.043
Most 0.032 N3 0.269
N 249 35964
adj R2 0.409 0.460
Predictive ability
MAE 0.074 0.039
%>|0.05| 46 29
%>|0.10| 22 7
t(mean=0) 1.612 0.571
JB 1.505 0.005
LB 123.00* 9.027
Note: Most data here is not directly comparable across models.
MAE=mean absolute error. JB=Jarque-Bera test [28].
LB=Ljung-Box, test result signiﬁcant at t0.001 [29].
Both models fail Reset and heteroscedasticity tests.
Models are estimated with White’s heteroscedasticity consistent
standard errors.
All coeﬃcient estimates are signiﬁcant at t0.10.
The EQ-5D model presented here is formally equivalent to that
presented in [5].
For mobility, for example, MOB2=MO, and MOB3
MOB2=MO+M2.
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reference to single index scores. This includes an
assessment of the degree of agreement between
dimension of the two instruments using the
Spearman rank correlation across the whole
sample and by patient group. The distribution of
responses across the dimensions in the two
instruments is also examined for the whole sample
and by patient group. Those patients who are
classiﬁed into the lowest or highest health state for
each instrument are looked at more closely in
terms of their distribution of responses across the
other instrument.
The second stage in the analysis will introduce
the preference-based indices. Basic descriptive
statistics including means, medians and ranges
are compared by instrument and by patient group.
The degree of agreement is also examined by
calculating the single measure intraclass correla-
tion coeﬃcient (ICC). This is done by using the
reliability analysis in SPSS ver. 10 (two-way
random eﬀects model based on absolute agree-
ment). Further, to examine the nature of the
relationship more closely, a series of OLS regres-
sions have been run to explore the relationship
between SF-6D indices and EQ-5D indices. The
models used are:
SF-6Dindex ¼ aþ b1EQ-5Dindexþ u ð1Þ
SF-6Dindex ¼ aþ b1EQ-5Dindexþ b2N3þ u ð2Þ
The regression analysis is not intended to suggest
that EQ-5D index numbers can or should be used
to predict SF-6D indices, or that SF-6D indices
can or should be explained in terms of EQ-5D
indices. It merely provides another way of under-
standing the relationship between them.
Results
Dimension-to-dimension comparison
Table 3 summarises the relationship between the
dimensions of the EQ-5D and the SF-6D in terms
of Spearman correlation coeﬃcients. There is
evidence for the convergent validity between
similar dimensions: between physical functioning
and mobility, between role limitation and social
functioning with usual activities, between pain and
pain/discomfort, and between mental health and
anxiety/depression. These correlations exceeded
the correlations between these and other dimen-
sions. The lowest correlations are observed be-
tween mental health and mobility, between mental
health and self care, and between physical
functioning and anxiety/depression, of the SF-6D
and the EQ-5D respectively.
Table 4 presents the distribution of SF-6D and
EQ-5D results. SF-6D indicates bimodal distribu-
tions in physical functioning, role limitation, social
functioning, and to some extent pain. This reﬂects
the heterogeneity in severity across the seven data
sets. Breaking this information down by disease
groups (not shown) indicates that for example,
while the majority of IBS and of Mp patients
report levels 1 or 2 physical functioning, an
overwhelming 92% of OA patients report level 6
on this dimension. However, none of this is
reﬂected in the EQ-5D results. A large proportion
of responses lie within levels 1 and 2, and for
example, only 0.2% of the whole sample (and none
of them OA patients) report level 3 mobility.
Overall, there is very little use of level 3 in four of
the ﬁve dimensions of EQ-5D. This suggests that
many patients feel that an ‘extreme’ problem in
EQ-5D is much worse than any of the worst levels
of the SF36 items used in SF-6D.
The EQ-5D has a larger proportion of respon-
dents in the top category of each dimension than
for the SF-6D (i.e. 3.6% to 34.6% compared to
17.1% to 72.2%). This suggests that the EQ-5D is
not capable of distinguishing between health states
close to full health. The extent of the distribution
across the SF-6D is somewhat negated by the
aggregation of some levels in the consistent version
of the SF-6D model. The ceiling eﬀect can be
Table 3. The correlation between SF-6D levels and EQ-
5D levels
EQ-5D SF-6D M SC UA PD AD
PF 0.58 0.51 0.58 0.39 0:14
RL 0.40 0.30 0.50 0.33 0.42
SF 0.47 0.43 0.56 0.38 0.34
P 0.46 0.39 0.59 0.60 0.30
MH 0:12 0:17 0.25 0.21 0.55
V 0.34 0.33 0.45 0.32 0.35
The correlations between like dimensions are indicated in bold.
The three least correlated dimension pairs are underlined.
EQ-5D dimensions: M: mobility; SC: self care; UA: usual
activities; PD: pain/discomfort; AD: anxiety/depression.
SF-6D dimensions: PF: physical functioning; RL: role limita-
tion; SF: social functioning; P: pain; MH: mental health; V:
vitality.
J. Brazier et al.878
Copyright # 2004 John Wiley & Sons, Ltd. Health Econ. 13: 873–884 (2004)
further explored by selecting those reporting full
health in one instrument to see what they report in
the other instrument. There are only 5 respondents
who report full health in SF-6D, and all of them
also report full health in EQ-5D, so there is not
much to be said of this subgroup. However, there
are 214 observations where the patient reports full
health in EQ-5D, of which only 12 (6%) report full
health in SF-6D. This means that, for the great
majority of those reporting full health in EQ-5D,
their health was not full in SF-6D. Table 5
summarises the SF-6D responses of these 214 by
dimension. This indicates that those in full health
in terms of EQ-5D may still have problems in
physical functioning, mental health, and vitality.
Vitality is not an EQ-5D dimension, so this to
some extent is expected. Of interest is that of those
who report 11111 in EQ-5D, 60% feels ‘tense or
downhearted and low’ a little (level 2) or some
(level 3) of the time.
There is only one observation (75+) where EQ-
5D=33333 and 12 observations where SF-
6D=645655 (2 with COPD, 2 with Lu, 7 with
OA, and 1 from 75+). These respondents do not
necessarily report the worst state in the alternative
instrument, but the numbers are too small to merit
generalisation. However, it is clear from the
distribution across the individual dimensions that
the SF-6D has larger proportion on its lowest level
of physical functioning and role limitation than
does the EQ-5D on mobility and usual activities
(i.e. 24.6% and 38.4% versus 0.2% and 10.5%).
For pain and mental health the proportions are
more alike (at 8.2% and 4.8% versus 16.9% and
3.9%).
The preference-based index numbers
The SF-6D mean index exceeds the EQ-5D mean
index across the whole sample by 0.045 (Table 6).
The mean diﬀerence varies between –0.015 for
patients suﬀering symptoms of the Menopause to
0.094 for patients with leg ulcers. The mean
diﬀerence is within 0.05 for all patient groups
except leg ulcers and osteoarthritis. ICC between
the indices for the whole sample was 0.51, ranging
from 0.28 for COPD and 0.55 for IBS.
For six out of the seven patient groups the mean
SF-6D index exceeds the EQ-5D. By contrast, the
median EQ-5D score exceeds the SF-6D in six
patient groups and by –0.082 for the whole
sample. This reversal in the sign of the diﬀerence
reﬂects the diﬀerent distributions of indices
produced by the two measures. The ranges
diﬀer markedly, with the range for the EQ-5D
covering –0.4 to 1.0 compared to 0.3 to 1.0 for the
SF-6D. This negative skew in the EQ-5D data
Table 4. SF-6D and EQ-5D results
(a) Distribution of SF-6D (%)
Level Physical functioning Role limitation Social functioning Pain Mental health Vitality
1 7.4 28.0 34.6 9.3 17.8 3.6
2 21.7 22.4 14.4 13.9 26.1 18.9
3 18.6 11.1 24.5 23.9 37.2 32.6
4 14.2 38.4 17.7 20.5 14.1 22.4
5 11.4 } 8.8 23.8 4.8 22.4
6 26.6 } } 8.5 } }
Total (n) 2339 2994 2320 2332 2333 3213
(b) Distribution of Eq-5D (%)
Level Mobility Self care Usual activities Pain/discomfort Anxiety/depression
1 39.9 72.2 35.8 17.1 52.5
2 59.9 26.8 53.7 66.0 43.6
3 0.2 1.0 10.5 16.9 3.9
Total (n) 2324 2295 2303 2313 2307
Modal level is in bold.
The distribution adds up to 100% by columns.
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results in the mean being lower than the median in
six out of seven cases. For the SF-6D mean
exceeds the median in all patient groups, though
the size of the diﬀerence is somewhat less. The EQ-
5D indices are also associated to higher standard
deviations.
A more detailed inspection of the plot of EQ-5D
to SF-6D reveals other marked diﬀerences between
the two measures (Figure 1). Whilst the overall
correlation is 0.66, the pattern is not linear. There
is a considerable degree of dispersion, with
negative indices on the EQ-5D being associated
with values on the SF-6D as high as 0.75.
Furthermore, SF-6D indices being spread across
a much narrower range compared to EQ-5D
indices has a ﬂoor eﬀect with a signiﬁcant
proportion of the SF-6D at or near the lowest
possible value being associated with a large range
of EQ-5D values. Conversely, the ceiling eﬀect of
EQ-5D relative to SF-6D can be observed in the
wide range in SF-6D indices of those with EQ-5D
index=1.00. Some of these respondents can have
quality adjustments by SF-6D as low as 0.56.
Another pattern is for EQ-5D indices to cluster.
This is especially so at the upper extreme, where
there is a large gap between EQ-5D index=1.00
and those less than 1.00. Finally, there is another
clear gap in the EQ-5D indices around 0.45. All
observations to the right of this gap have N3=0 in
the MVH A1 tariﬀ, and all those to the left have
N3=1, indicating that the N3 term used in the
modelling is causing this bimodal distribution of
EQ-5D indices.
Table 7 summarises the ﬁrst and second regres-
sion models on the whole sample, and the second
model by patient group. The patient speciﬁc
Table 5. Ceiling eﬀects of EQ-5D. Distribution of SF-6D of those with EQ-5D = 11111
Level Physical functioning Role limitation Social functioning Pain Mental health Vitality
1 29.0 76.7 82.1 45.8 35.2 7.5
2 49.8 10.0 10.8 32.1 38.5 51.4
3 11.1 8.6 5.2 18.9 22.1 29.2
4 2.4 4.8 1.4 2.4 2.3 9.4
5 3.4 } 0.5 0.9 1.9 2.4
6 4.3 } } 0.0 } }
Total (n) 207 210 212 212 213 212
Modal level is in bold. The distribution adds up to 100% by columns.
Table 6. SF-6D and EQ-5D indices by disease group
n Mean SD Median Minimum Maximum ICC of indices
Whole EQ5D index 2298 0.586 0.309 0.691 0.594 1.000 0.51
SF6D index 2192 0.631 0.149 0.609 0.300 1.000
LBP EQ5D index 265 0.636 0.266 0.691 0.181 1.000 0.53
SF6D index 263 0.658 0.144 0.634 0.370 1.000
COPD EQ5D index 255 0.540 0.309 0.620 0.349 1.000 0.28
SF6D index 230 0.572 0.112 0.577 0.296 0.944
IBS EQ5D index 314 0.662 0.260 0.725 0.077 1.000 0.55
SF6D index 296 0.666 0.146 0.628 0.373 1.000
Lu EQ5D index 431 0.552 0.307 0.620 0.239 1.000 0.50
SF6D index 430 0.647 0.145 0.626 0.296 1.000
OA EQ5D index 428 0.442 0.336 0.587 0.239 1.000 0.38
SF6D index 404 0.521 0.114 0.499 0.296 0.948
75+ EQ5D index 320 0.614 0.299 0.691 0.594 1.000 0.49
SF6D index 291 0.662 0.141 0.651 0.296 1.000
Mp EQ5D index 285 0.729 0.262 0.796 0.181 1.000 0.53
SF6D index 278 0.716 0.143 0.718 0.370 1.000
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coeﬃcients indicate the relationship is not uniform
between the two index numbers. The patient
speciﬁc b1 coeﬃcients were found to be similar
for IBS, leg ulcer, the elderly and menopausal
groups, but statistically diﬀerent for Lower Back
pain, COPD and Osteoarthritis. Another set of
regressions were run where two sets of estimations
were obtained for those with N3=0 and those
with N3=1, but the diﬀerences in coeﬃcients were
small, and therefore not reported here. As can be
expected from the scatter plot, the inclusion of the
N3 term will improve the explanatory power
somewhat, and makes the b1 coeﬃcient much larger.
Discussion
It is important to compare the diﬀerent preference-
based measures of health in order to inform an
important debate on the choice of instrument.
This paper has sought to address this question
by comparing two of the more widely used
generic measures in seven patient groups. The
results presented in this paper broadly support
the following conclusions. There is considerable
overlap in the descriptive systems of the two
instruments and signiﬁcant agreement between
the indices that they generate. A simple compar-
ison of mean SF-6D and EQ-5D indices across
the whole sample of patients found that on
average SF-6D generates values that exceed
the EQ-5D. The mean diﬀerence, though statisti-
cally signiﬁcant, is only 0.045. This high degree
of convergence provides some support for their
construct validity [2]. However, this apparent
similarity hides a signiﬁcant degree of disagree-
ment between these two measures. The intraclass
correlation coeﬃcient for the whole sample
is 0.51. Furthermore, depending on the patient
group, the diﬀerence between the SF-6D and
EQ-5D ranges from 0.015 to 0.094 and the
intraclass correlation coeﬃcient ranges from
0.27 to 0.55. The median shows a diﬀerent
pattern, with the EQ-5D value exceeding the
SF-6D value. This reﬂects the considerable
negative skew in the EQ-5D values. The plot
of the two indices for the whole group
reveals marked diﬀerences over the range of ill
health.
The similarity in mean health state values across
the patient groups implies that for curative
interventions aimed restoring patients to full
health the size of the diﬀerence in estimated QALY
gain may not be great for many of these
conditions, with a diﬀerence of less than 0.05 for
ﬁve out of the seven conditions. However, most
interventions do not restore people to full health
but achieve some partial relief, where the variation
in the relationship over the range of ill health
could have signiﬁcant implications for the estimate
of QALY gain. It is therefore important to
understand the reason for these diﬀerences in
order to inform the debate concerning which
instrument to use and whether or not there is a
case for revising one or both of these measures to
solve any apparent limitations. This involved a
discussion of their descriptive content, the valua-
tion methods and the resultant scoring algorithm.
EQ5D index
1.00.80.60.40.2-0.0-0.2-0.4-0.6
SF
6D
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-0.6
those with N3=1
those with N3=0
Figure 1. SF-6D indices vs EQ-5D indices
Table 7. Regressing SF-6D indices on EQ-5D indices
Adjusted R2 a b1 b2
Whole (1) 0.44 0.44 0.33 }
Whole (2) 0.50 0.26 0.56 0.20
LBP 0.50 0.19 0.67 0.27
COPD 0.19 0.42 0.25 0.07
IBS 0.46 0.22 0.63 0.21
Lu 0.54 0.30 0.55 0.18
OA 0.48 0.29 0.43 0.14
75+ 0.46 0.31 0.51 0.17
Mp 0.45 0.28 0.56 0.20
The regression ‘whole (1)’ is: SF-6Dindex=a+b1 EQindex+u.
All others are: SF-6Dindex =a+b1 EQindex+b2N3+u. All
coeﬃcients have p50.001 except b2 for COPD where p=0.03.
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Descriptive content
The descriptive systems would seem to account for
some part of the diﬀerence. The SF-6D is more
concentrated at the milder end of health problems,
whereas the EQ-5D covers a larger range and
consequently suﬀers from being cruder. Around a
third of respondents to the valuation survey
thought that the worse state deﬁned by the SF-
6D was worse than death compared to a great
majority for the EQ-5D. Correspondingly, at the
upper end the EQ-5D has a far larger proportion
on the top level than the SF-6D and that those on
the ceiling of the EQ-5D can be diﬀerentiated by
the SF-6D in terms of health problems. A similar
result was found in a study of liver transplant
patients (see Louise L, Bryan S. An empirical
comparison of EQ-5D and SF-6D in liver trans-
plant patients. Health Econ, in press). The two
health classiﬁcations cover similar domains (except
for energy), but at least for physical functioning,
self care and usual activities describe diﬀerent
severity levels. For these dimensions the diﬀerent
levels are described as limits to activities. In the
EQ-5D, the lowest levels of the comparable
domains are described as unable and conﬁned to
bed. The SF-6D has a far larger number on the
ﬂoor of these dimensions, but this does not extend
to the dimensions for pain and mental health.
This diﬀerence between the dimensions is
supported by the larger mean diﬀerences for
conditions focused more on physical health
problems such as leg ulcers and osteoarthritis
compared to those more focused on pain and other
forms of discomfort such as lower back pain and
IBS. The implication would be that the researcher
should choose between the instruments on the
bases of the appropriateness of the descriptive
system in terms of the severity of problems
typically encountered in the patient group for
each domain.
Valuation methods
Unfortunately the conclusion is not quite as
simple, since we do not fully understand the
consequences of the diﬀerences in valuation
methods. The main diﬀerence in methods is in
the valuation technique. It has been suggested that
for a range of reasons SG would be expected to
generate higher values than TTO across the entire
severity range and this has been found in a number
of studies [21]. A study undertaken in York
comparing their own variants of TTO and SG,
however, found evidence for a crossover. SG props
values exceeded TTO props up to VAS values of
0.4, but then there was a cross over with TTO
values exceeding SG values [22]. The size and
pattern of the diﬀerence between TTO and SG
depends, therefore, on the variants of the two
techniques being used. We have undertaken such a
comparison and provisional results have been
reported elsewhere [23].
Another diﬀerence is that the SF-6D group uses
a ‘two stage’, or ‘chained’ SG. That is, ﬁrst the
health states are valued using perfect health and
the worst health state as anchor points. So in the
ﬁrst instance, death is no part of the SG. Then the
worst state is valued using a standard gamble with
the anchor points perfect health and death. The
primary reason to use a chained SG is the notion
that subjects might be reluctant to trade oﬀ health
against immediate death. There is evidence that
chained values may be higher than value obtained
[24–26]. This would mean that the values of the
SF-6D would show upward shift compared to the
MVH valuation of the EQ-5D which did not use a
chained procedure.
The scoring algorithms
The algorithms presented in Table 2 are the result
of the descriptive system and the valuation method
and therefore in one sense examining the algo-
rithms does not add any additional explanations.
However, there are two features of the algorithm
that have an important eﬀect on the indices they
generate: the interpretation of the constant term
and the interaction terms.
The expected value of the estimated constant term
in the models was one, but in practice it was found to
be signiﬁcantly smaller than one. The SF-6D study
made a theoretical case for restricting the intercept to
unity [11]. The SG value for each state has been
estimated by assuming SF-6D state 111111 health is
to equal one. Whereas the EQ-5D study interprets
the diﬀerence between the estimated constant and
one as ‘any move away from full health’ (p. 1104);
however, this has no theoretical justiﬁcation. This
diﬀerence in use of the treatment of the constant
term would increase the value of all ill health
states deﬁned by the SF-6D compared to the EQ-
5D. It results in the large gap between EQ-5D state
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11111 with a value of 1.0 and the next state a value
of 0.88.
Both studies accounted for interaction eﬀects in
a similar way. For the SF-6D the interaction term
is a simple dummy, MOST, which takes the value
1 if any dimension in the health state is at the
‘most severe’ level, and 0 otherwise. ‘Most severe’
is deﬁned as level 6 for physical functioning and
pain, levels 4 and 5 for social functioning and
mental health and level 5 for vitality. For the EQ-
5D, N3 is a very similar dummy variable that takes
the value 1 when any dimension is at level 3, and 0
if otherwise. The N3 term has a coeﬃcient of
0.269 compared to that for MOST of 0.032.
The N3 together with the value associated with a
move from level 2 to 3 of 0.1–0.3 results in
another large gap in the distribution of the EQ-5D
index.
Conclusion
It is important not to lose sight of the key ﬁnding
that at the mean level these instruments produced
indices that were within 0.05 of each other.
However, this does not imply that these two
instruments can be used interchangeably since they
generate diﬀerent indices over the range of ill
health. Such diﬀerences have been found between
other generic preference-based measures [27] (See
Louise L, Bryan S. An empirical comparision of
EQ-5D and SF-6D in liver transplant patients.
Health Econ, in press; O’Brien BJ, Spath M,
Blackhouse G, Severens JL, Brazier JE. A view
from the Bridge: agreement between the SF-6D
utility algorithm and the Health Utilities Index.
Health Econ, accepted). These results raise the
important research question of why diﬀerent
generic preference-based measures are giving
diﬀerent values. To address this question it would
be necessary to extend this comparison to other
data sets across the full range of ill health. It would
also be important to compare the variants of the
valuation methods used for each instrument [23].
The study has other important implications for
further work. One is to extend this comparative
work to other preference-based measures of health,
and this paper demonstrates the diﬀerent ways in
which it is possible to compare measures. A second
is to estimate the impact of the diﬀerences between
these and other preference-based measures on the
estimates of the gains from health care interven-
tions. Another implication would be to consider
revising one or both of these instruments to
overcome their weaknesses, particularly in their
descriptive systems. It could be possible, for
example, to add more intermediate levels to the
EQ-5D or, by the same token, add lower levels to
the SF-6D dimensions, at least for the physical
functioning and role limitation dimensions.
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Notes
a. Those wishing to use the EQ-5D should contact the
EuroQol Business Management, PO Box 4443, 3006
AK Rotterdam, The Netherlands; http://www.
euroqol.org/
b. Those wishing to use the SF-6D should contact SF-
6D, Sheﬃeld Health Economics Group, School of
Health and Related Research, The University of
Sheﬃeld, Regent Court, 30 Regent Street, Sheﬃeld,
S1 4DA, UK.
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